← All Joint CORP filings

Joint CORP DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
JYNT
Joint CORP
DEF: The Joint Corp. Reports 2025 Progress and Outlines Future Growth
The Joint Corp. announces a return to profitability in 2025 with $2.9 million net income and 13.9% Adjusted EBITDA growth, driven by refranchising efforts and strategic initiatives.
NASDAQ
JYNT
Joint CORP
DEFA14A: The Joint Corp. Files Definitive Proxy Statement
The Joint Corp. has filed a definitive proxy statement with the SEC.
NASDAQ
JYNT
Joint CORP
DEF 14A: The Joint Corp. Aims for Growth: Proxy Statement Reveals Strategic Plans and Executive Compensation
The Joint Corp.'s proxy statement outlines the company's strategic initiatives to become a world-class franchisor, improve profitability, and drive growth, while also detailing executive compensation and corporate governance matters.
NASDAQ
JYNT
Joint CORP
DEFA14A: The Joint Corp Addresses ISS Concerns Over 2024 Incentive Stock Plan Ahead of Annual Meeting
The Joint Corp. issues a supplement to its proxy statement addressing concerns raised by Institutional Shareholder Services (ISS) regarding the approval of the 2024 Incentive Stock Plan and clarifying director attendance at board meetings.
NASDAQ
JYNT
Joint CORP
DEF 14A: The Joint Corp Aims for Chiropractic Dominance: Refranchising Strategy and 2024 Incentive Plan Unveiled
The Joint Corp outlines its strategic vision to champion chiropractic care through refranchising, brand elevation, and a new incentive stock plan.